Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Stock data | 2024 | Change |
---|---|---|
Price | $0.137 | N/A |
Market Cap | $10.11M | N/A |
Shares Outstanding | 73.83M | N/A |
Employees | 0 | N/A |